Abstract
Standard therapy for chemosensitive relapsed diffuse large B-cell lymphoma (DLBCL) is high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) based on the results of the Parma study (
NEJM
1995
;333
:1540
–5Author notes
Disclosure:Membership Information: Ephraim P. Hochberg, MD; Advisory Board: Genentech, Inc; Speaker’s Bureau: Genentech, Inc, Biogen Idec, Inc, Amgen, Inc.; David C. Fisher, MD; Speaker’s Bureau: GENIE, BEN.
2007, The American Society of Hematology
2007
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal